Endocrine Abstracts

The control of acromegaly with drug therapy (DT) by fg-SRLs is achieved only in 40–50% of cases, due to the heterogeneous composition of somatotrophic tumors. In order to optimize DT stratification of clinical and immunophenotypic biomarkers which make it possible to predict the long-term effectiveness of fg-SRLs at early stages is required. The aim of the work was to assess the informativeness of pharmacotherapeutic testing (% of decrease of IGF-1 level after 3 and 6 mon...

The aim: To determine the prognostic parameters affecting the course of acromegaly (A.) and the effectiveness of drug therapy (MT).Matherials and methods: 779 patients of A. [218 men (28%)] aged 60 (48/69) years, [Me(25%/75%)] were included in the Moscow register. The prevalence of A. in Moscow is 61.6; the incidence is 4.0 cases/million inhabitants. The treatment algorithm included surgical aid (495 patients), primary (I) or secondary (II) MT (584) and ...

The efficiency of the prolonged medical therapy of acromegaly with the somatostatin analogues (SA) strictly correlates with the initial sensitivity to the drug. Before the onset of SA therapy 114 patients with acromegaly (35 men and 79 women) aged 54 (48/61) years old (Me (25/75%) underwent the test with Octreotide (Sandostatin®): 300 μg sc within 3 days. The decrease of IGF1 level positively correlated with the age of the acromegaly onset (r=0.38) and negativ...

The efficacy and safety of saxagliptin – a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for extended inhibition of the DPP-4 enzyme – was investigated in two double-blind, randomised trials (CV181-014/Study 1 and CV181-039/Study 2), either as add-on therapy in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin alone (HbA1c 7.0–10.0%) or as initial combination therapy with metformin i...